Table of Contents

Entacapone

Primer

Entacapone is an inhibitor of catechol-O-methyltransferase (COMT). It is used in combination with levodopa/carbidopa (Sinemet) to treat the end-of-dose wearing-off effects of Parkinson's disease. Entacapone helps to increase levodopa and carbidopa levels.

Dosing

Adverse Events

Impulse-Control Disorders (ICDs)

  • Impulse-control disorders (ICDs) such as compulsive gambling, buying, sexual, and eating behaviours, are a serious and increasingly recognized complication in Parkinson's disease (PD), occurring in up to 20% of PD patients over the course of their illness.
  • Related behaviours include punding (stereotyped, repetitive, purposeless behaviours), dopamine dysregulation syndrome (DDS), levodopa misuse (compulsive medication overuse), hobbyism (e.g. - compulsive internet use, artistic endeavours, and writing), and hypersexuality or paraphilias.
  • These disorders have a significant impact on quality of life and function, strain interpersonal relationships, and worsen caregiver burden, and are associated with significant psychiatric comorbidity.
  • Patients often do not report these behaviours due to shame or guilt, and so it is important to ask these questions directly!
  • Management includes decreasing the dose of the offending agent (usually a dopamine agonist) or completely stopping it.
    • It may take upto 4 months for ICD symptoms to dissipate after the agonist is discontinued.
    • Once patients gain insight into their behaviour they are at higher risk of suicide.